Compare DOGZ & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOGZ | TNYA |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 178.5M |
| IPO Year | 2017 | 2021 |
| Metric | DOGZ | TNYA |
|---|---|---|
| Price | $1.21 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 33.8K | ★ 2.8M |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.36 |
| 52 Week High | $30.00 | $2.35 |
| Indicator | DOGZ | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 30.85 | 43.98 |
| Support Level | $1.02 | $0.65 |
| Resistance Level | $1.45 | $0.82 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 31.88 | 7.30 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.